Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04937319 formulations in type 2 diabetes
NCT02206607Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2014
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nerigliatin in type 2 diabetes mellitus (T2DM), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time and Weighted-Mean-Daily-Glucose. Started Sep 2014; status: completed.
02
Drugs
nerigliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02206607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02206607.